ELI LILLY & (LLY) Company Report

$3.5 billion investment to build a Lehigh Valley, PA, facility for next-generation weight-loss therapies, including retatrutide.
Facility will create 850 high-value jobs and generate 2,000 construction jobs, with operations starting in 2031.
Marks Lilly’s 10th U.S. manufacturing site since 2020 and 4th announced since February 2025, part of over $50 billion in capital commitments to expand U.S. capacity.

2 days ago

Press Release

Lilly signs multi-billion gene therapy deals

LLY

New Projects/Investments

Lilly entered a tech-transfer deal with Seamless Therapeutics worth up to $1.12 billion to develop programmable recombinase treatments for hearing loss.
Lilly partnered with Repertoire Immune Medicines on tolerizing T-cell therapies for autoimmune diseases, including an $85 million upfront payment and up to $1.84 billion in milestones plus royalties.
These collaborations extend Lilly’s pipeline beyond weight-loss drugs, building on its 2025 acquisition of Verve and prior gene-editing and RNA investments.
TipRanks reports a consensus Strong Buy from 20 analysts on Lilly stock, with an average price target of $1,191.37 (≈12% upside).

3 days ago

Morningstar

Lilly-backed Coventry issues $750 million asset-backed notes under LILY program

LLY

Debt Issuance

New Projects/Investments

Coventry completed its third securitization under the LILY life insurance–backed financing program, issuing $750 million in asset-backed notes and bringing cumulative LILY financing to $750 million since April 2025.
The financing is secured by long-term life insurance assets, providing investors with stable collateral, predictable cash flows, and low correlation to traditional markets, supported by rigorous underwriting, analytics, and structural protections.
As a leader in the life insurance secondary market, Coventry has transacted over 21,000 policies, completed >$50 billion in related transactions, paid >$6 billion to policyholders, and originated >$10 billion in policy loans.

4 days ago

Press Release

Eli Lilly signs $1.12B gene-editing collaboration

LLY

New Projects/Investments

Eli Lilly enters a collaboration with Seamless Therapeutics worth up to $1.12 billion to develop and commercialize gene-editing recombinase therapies for genetic hearing loss.
The agreement includes upfront payments, development funding, milestone payments and tiered royalties.
The deal builds on Lilly’s existing hearing-loss strategy, including its 2022 acquisition of Akouos and a 2024 trial restoring auditory function in an 11-year-old patient.
Lilly shares fell about 2–2.4% amid a healthcare sell-off and ahead of a Federal Reserve decision, trading between $1,012.09 and $1,038.96 on the announcement day.
Analysts highlight Lilly’s strong financial position, with a market cap of $909.44 billion, current ratio 1.55, quick ratio 1.24, debt-to-equity 1.79 and Altman Z-Score 7.82.

4 days ago

Bloomberg

Roche reports CT-388 delivers 22.5% weight loss

LLY

Product Launch

M&A

New Projects/Investments

Roche’s Genentech unit reported positive Phase II results for CT-388, a once-weekly dual GLP-1/GIP injection, showing a 22.5% placebo-adjusted weight loss at 48 weeks at the highest 24 mg dose.
54% of participants on the top dose achieved resolution of obesity, and nearly 50% lost 20% or more of body weight by week 48.
Safety and tolerability were consistent with the incretin class, with most gastrointestinal effects described as mild to moderate and a low 5.9% discontinuation rate due to health impacts.
Roche acquired the CT-388 program through its $3.1 billion purchase of Carmot Therapeutics in 2023.
The company plans to start Phase III studies this quarter and expects CT-388 to reach the market by 2028 with peak sales above CHF 3 billion.

6 days ago

Bloomberg

Eli Lilly’s Sofetabart Mipitecan Receives FDA Breakthrough Therapy Designation

LLY

The FDA granted Breakthrough Therapy designation to Eli Lilly’s sofetabart mipitecan for adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after prior bevacizumab and mirvetuximab soravtansine treatment.
Phase 1a/b data (March 9, 2025 cutoff) in 58 efficacy-evaluable patients showed an overall response rate of 45% (3% unconfirmed CR, 41% PR) and a disease control rate of 74%.
Initial safety results indicated low rates of interstitial lung disease, peripheral neuropathy, and alopecia, with no significant ocular toxicity reported.
The program has advanced into a Phase 3 trial under the expedited review pathway provided by the designation.

Jan 20, 2026, 1:56 PM

Morningstar

Lilly’s sofetabart mipitecan receives FDA Breakthrough Therapy designation

LLY

FDA granted Breakthrough Therapy designation to sofetabart mipitecan (LY4170156) for treating platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who had prior bevacizumab and mirvetuximab soravtansine.
The designation is based on Phase 1a/b study results showing responses across all folate receptor α expression levels and a favorable tolerability profile.
Lilly has initiated the global Phase 3 FRAmework-01 trial, evaluating the drug as monotherapy in platinum-resistant ovarian cancer and in combination with bevacizumab for platinum-sensitive disease.
Ovarian cancer is the fifth leading cause of cancer death among U.S. women, with around 70% of patients experiencing recurrence after platinum-based chemotherapy and limited options for platinum-resistant cases.

Jan 20, 2026, 12:45 PM

Press Release

Eli Lilly outlines obesity and pipeline strategy at JPMorgan conference

LLY

Product Launch

New Projects/Investments

Eli Lilly expects Q2 approval for oral GLP-1 orforglipron under the FDA’s Priority Review Voucher Program and has resolved prior supply shortages; LillyDirect now serves ~1 million patients.
Medicare Part D will cover obesity treatments at $50 OOP; Medicaid eligibility is expanding, while commercial coverage remains uneven at <60% of employer plans, with new PBM carve-out solutions launching in 2026.
Lilly has launched 24 new molecular entities over the past decade and is ~3.5 years faster than peers from candidate selection to first introduction; late-stage programs include Lp(a) siRNA/oral therapies, four Phase 3 oncology assets, and Alzheimer’s candidates.
The oral GLP-1 strategy targets three use cases—needle aversion, polypharmacy convenience, and emerging-market reach—with maintenance-phase switching studies to orforglipron following parenteral therapies.

Jan 13, 2026, 10:15 PM

Transcript

Lilly outlines obesity portfolio expansion and $55B investment

LLY

New Projects/Investments

Entering a new era in obesity treatment by expanding from a single marketed product to a broad portfolio with global launches and 13 manufacturing sites under construction to improve supply and coverage.
Maintaining a broad pipeline with five late-phase incretin/amylin candidates, six additional clinical-stage programs, and 34 discovery efforts targeting obesity, diabetes, sleep apnea, pain, cardiovascular, renal, and hepatic diseases—aiming to help 1 billion people.
Committing $55 billion to create a sustainable advantage, including 13 new R&D sites globally, and driving 24 NME launches from 2015–2025 with a development timeline 3.5 years faster than industry average.
Focusing 75% of new clinical medicines outside incretins/amylins and advancing indications in elevated lipoprotein(a) (63 M patients), chronic pain (51 M), early Alzheimer’s (20 M), and early breast cancer (3 M).

Jan 13, 2026, 10:15 PM

Presentation

Eli Lilly outlines 2026 obesity and pipeline strategy at J.P. Morgan Healthcare Conference

LLY

Product Launch

New Projects/Investments

Eli Lilly celebrates its 150th anniversary and reports strong momentum in its metabolic franchise, highlighting retatrutide achieving up to 29% weight loss and four additional obesity candidates in phase III.
The company resolved 2024 supply shortages and scaled its LillyDirect platform to serve ~1 million patients monthly, with vials becoming the second-best-selling obesity treatment.
Oral GLP-1 candidate orforglipron has been submitted under the FDA Priority Review Voucher program, with approval anticipated in Q2 2026, ahead of the Medicare Part D obesity benefit expansion.
U.S. access expansion includes Medicare Part D coverage for obesity drugs with $50 out-of-pocket costs and planned Medicaid rollouts, expected to surpass current commercial penetration.
Beyond obesity, the pipeline is diversified with late-stage assets in Lp(a) (lepodisiran, muvalaplin), oncology (four phase III programs), and Alzheimer’s candidates (remternetug, donanemab), supported by accelerated development capabilities.